At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02315 BIOCYTOGEN-B
Closed 03-12 16:08:20
55.450
-1.050
-1.86%
High60.500
Low53.800
Vol463.68K
Open56.800
D1 Closing56.500
Amplitude11.86%
Mkt Cap24.79B
Tradable Cap6.15B
Total Shares447.00M
T/O25.97M
T/O Rate0.42%
Tradable Shares111.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Dual Boost from Policy and R&D! Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Rises Over 1%, Led by Biocytogen-B and PegBio Co-B
BIOCYTOGEN-B (02315) Issues 2025 Performance Forecast: Expects Net Profit Attributable to Owners of RMB162 Million to RMB182 Million, Up 384.26% to 443.88% YoY
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a China-based company primarily engaged in the provision of innovative animal models and pre-clinical pharmaceutical research and development services based on its independently developed gene-editing technology. The Company utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The Company is also engaged in the provision of gene-editing services. The Company operates its businesses in the domestic market and overseas markets.